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Abstract
The diagnosis of neuroendocrine neoplasia (NEN) is often made at an advanced stage of disease, including hepatic metastasis. At
this point, the primary may still be unknown and sometimes cannot even be detected by functional imaging, especially in very
small tumors of the pancreas (pan) and small intestinal (si) entities. The site of the primary may be based on biopsy specimens of
the liver applying a specific set of markers. Specimens of liver metastases from 87 patients with NENswere studied. In retrospect,
50 patients had si and 37 pan NENs. Tissue samples were evaluated by immunohistochemistry. The markers applied were insulin
gene enhancer protein Islet-1 (ISL-1), homeobox protein CDX-2 (CDX2), thyroid transcription factor 1 (TTF-1), and serotonin.
Positive stains for CDX2 were documented in 43 (86%) and for serotonin in 45 (90%) of 50 siNENs. Three panNENs were
positive for CDX2 and one for serotonin, respectively. ISL-1 was negative throughout in siNENs and also negative in 8 of 50
panNENs (21.6%). TTF-1 was negative in more than 90% of the specimens of either entity. Immunohistochemical markers in
liver metastasis can lead the way to the site of the primary NEN. They should always be used in combined clusters.
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Introduction
Neuroendocrine neoplasia of the pancreas (pan) and especial-
ly the small intestine (si) is rare [1, 2], frequently has a long
asymptomatic course [3, 4], and remains undiagnosed until
radiological examinations are done due to diffuse abdominal
symptomatology [5].
As shown recently, 43 (23.8%) of 181 patients with NEN
located in various sites of the gastroenteropancreatic tract were
diagnosed at presentation with liver metastasis. In five (1.8%)
additional patients, the primary could not be located. Even func-
tional imaging failed to identify the primary in these patients [1].
The hint to the origin of the Bunknown primary^ may occa-
sionally be based on biopsies of the liver applying specific
immunohistochemical markers [6]. Insulin gene enhancer pro-
tein Islet-1 (ISL-1), thyroid transcription factor 1 (TTF-1), se-
rotonin, and homeobox protein CDX-2 (CDX2) are transcrip-
tion factors that can be expressed in pan and siNENs [7, 8].
To our knowledge, no systematic studies on differences
regarding the expression of those markers in liver metastases
of either entity have so far been published.
Methods
Fifty patients with siNENs of the ileum (20 females, 30 males;
mean age 61, range 37–81) and 37 patients with panNENs (21
females, 16 males; mean age 54, range 25–81) and synchro-
nous liver metastasis were retrospectively analyzed. The me-
tastases were evaluated histologically, and immunohistochem-
ical staining of chromogranin A, synaptophysin, Ki-67, ISL-1,
TTF-1, CDX2, and serotonin was performed.
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Tumor tissue was routinely formalin-fixed and paraffin-
embedded. Hematoxylin and eosin staining was applied to
3-μm sections of each block. Immunostainings against prolif-
eration marker Ki-67 antigen (Molecular Immunology Borstel
1 [MIB-1] mouse monoclonal, Novocastra, Newcastle, UK,
dilution 1:20), CDX2 (1H9 mouse monoclonal, abcam,
Cambridge, UK, undiluted), ISL-1 (1H9 mouse monoclonal,
abcam, Cambridge, UK, dilution 1:400), TTF-1 (SP141 rabbit
monoclonal, Ventana, Tucson, Arizona, USA, undiluted), and
serotonin (5HT-H209 mouse monoclonal, DakoCytomation,
Denmark, dilution 1:100) were performed using an automatic
immunostainer (Ventana Medical Systems Inc., BenchMark®
or BenchMark® ULTRA, Tucson, Arizona, USA). For anti-
gen retrieval, slides for Ki-67, CDX2, ISL-1, and TTF-1 stain-
ing were boiled with a commercially available puffer (Ventana
Medical Systems Inc., Cell Conditioning 1, Tucson, Arizona,
USA) for 256, 256, 64, and 180 min, respectively. A commer-
cially available amplification kit (Ventana Medical Systems
Inc., Amplification Kit, Tucson, Arizona, USA) was used
for Ki-67 staining. Protease 1 pretreatment (for 8 min) was
applied for serotonin staining.
The histologies of all cases were reviewed by one experi-
enced pathologist (O.K.), classified according to the WHO
classification outlined in 2017 [9, 10] and staged according
to the European Neuroendocrine Tumor Society guidelines of
2006 and Union international contre le cancer 2010 [9–11].
For grading, the Ki-67 labeling index with MIB-1 antibody
was used and the Ki-67 index was assessed in 500 tumor cells
in areas in which the highest nuclear labeling was observed
using an eye grid ocular. Expression of ISL-1, TTF-1, CDX2,
and serotonin was evaluated semiquantitatively as follows: no
tumor staining (−), weak: staining in ≤ 10% (+), moderate:
staining in > 10 and < 100% (++), and strong: 100% of cells
(+++).
Results
All 87 liver metastases were of neuroendocrine origin con-
firmed by both synaptophysin and chromogranin A expres-
sion. The primary tumor was detected with further evaluations
of the patients (functional imaging, endoscopic ultrasound
with biopsy), and adequate treatment was performed as feasi-
ble. The immunohistochemic profile of the primary was iden-
tical to the liver metastasis in all cases. The details of the
staining patterns are summarized in Table 1.
CDX2
The stains for CDX2 were at least moderately positive in 92%
of the siNENs and negative in 92% of the panNENs.
ISL-1
ISL-1 was negative in all siNENs, whereas 75% of the pan
tumors showed at least a moderate stain.
Serotonin
Serotonin showed strong positive stains in 90% of the
siNENs, whereas it was moderately positive in only one
panNEN (2.7%).
TTF-1
Immunostaining for TTF-1 was negative in most siNENs
(96%) and panNENs (92%).
Combined Staining
Positive staining of CDX2 and serotonin yielded an almost
100% specificity for the siNENs. Photomicrographs of the
typical staining pattern of liver metastasis of an ileal NEN
compared to a pancreatic NEN are shown in Fig. 1.
Table 1 Staining pattern in siNENs and panNENs
siNEN n = 50 (%) panNEN n = 37 (%)
Serotonin
+++ 45 (90) 0
++ 0 1 (2.7)
+ 0 0
− 5 (10) 36 (97.3)
CDX-2
+++ 43 (86) 1 (2.7)
++ 3 (6) 0
+ 0 2 (5.4)
− 4 (8) 34 (91.9)
ISL-1
+++ 0 24 (64.9)
++ 0 4 (10.8)
+ 0 1 (2.7)
− 50 (100) 8 (21.6)
TTF-1
+++ 2 (4) 3 (8.1)
++ 0 0
+ 0 0
− 48 (96) 34 (91.9)
Semiquantitative analysis: (−) no staining, (+) weak staining ≤ 10%, (++)
moderate staining > 10 and < 100%, (+++) strong staining 100%
Si small intestine (ileal), pan pancreatic, NEN neuroendocrine neoplasia
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Discussion
Patients with NENs frequently share a long way of suffering
due to uncertainty. Unspecific abdominal symptoms lead to
radiological examinations of liver lesions, and biopsy may
evidence NENs. The journey then continues, as the primary
is still missing. As shown recently [1], at least 2% of all NENs
are diagnosed with an unknown primary. In this study, the
expression of various immunohistochemical markers in the
liver metastases of subjects with NEN was examined and the
frequency of the positivity of the set of markers was analyzed.
Retrospectively, the staining quality of the markers was cor-
related with the sites of the NEN, by definition being either the
si or the pan. The results of the analysis applying a specific set
of neuroendocrine markers on liver biopsies should help to
gain information concerning the possible sites of the NEN in
patients with unknown primary but liver metastasis.
Serotonin has been proposed to be a potent marker for
siNENs in biopsies [6]. In the current series, however, seroto-
nin was positive in 90% of the siNENs and only moderately
positive in one panNEN, thus being consistent with the liter-
ature [12] and resulting in high levels of sensitivity and spec-
ificity. While CDX2 has been reported to be positive in almost
all siNENs [13–15], we can only confirm that it was at least
moderately positive in 90% in our series. CDX2 was negative
in over 90% of the panNENs, thus showing higher specificity
than previous findings [13, 16] and suggesting that CDX2 is a
key marker (in combination with serotonin) to differentiate
siNENs from panNENs.
ISL-1 was seen to be an ideal marker to exclude siNENs, as
no positive stain was found in our specimens. In line with
other authors’ findings [17–19], however, panNENs can nei-
ther be excluded nor confirmed with this single marker, as
more than 20% of the liver metastases of panNENs in our
series were immunohistochemically negative for ISL-1.
TTF-1 should not be considered a valuable marker to dis-
tinguish between siNENs and panNENs, as the vast majority
of liver metastases of either entity were negative for TTF-1
labeling. Still, it remains highly useful to discriminate
gastroenteropancreatic NENs from those of the lung [20].
In the current study, the combination of these markers was
applied to differentiate siNENs with ileal primaries from
panNENs. As demonstrated, the combination of positivity
for CDX2 and serotonin in liver metastasis showed an almost
100% level of specificity for NENs of si origin. Therefore, (at
least) this combination of markers should be used when con-
sidering si provenance in patients with liver metastasis and an
unknown primary. Furthermore, functional imaging should be
applied in any patient with a metastatic NEN. Therefore, im-
munohistochemical markers must always be seen in connec-
tion with clinical and diagnostic findings to serve the patient
best. A single marker cannot replace the diagnostic algorithm
in complex neuroendocrine tumors.
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Fig. 1 The top row shows the typical staining pattern of a neuroendocrine liver metastasis of pancreatic provenience with strong positivity of ISL-1,
whereas the bottom row illustrates the staining pattern of a liver metastasis of an ileal NEN, yielding positivity for serotonin and CDX2
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